Investigation on Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Doses of a Long-acting GLP-1 Analogue in Healthy Male Subjects and Male Subjects With Type 2 Diabetes

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 17 Sep 2021

Price :

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

18 Dec 2018 Results assessing safety of semaglutide in type 2 diabetes patients, published in the Clinical Pharmacokinetics.
15 Sep 2017 Results assessing safety, tolerability and pharmacokinetics of multiple once-daily dosing of oral semaglutide in healthy males and in males with type 2 diabetes, presented at the 53rd Annual Meeting of the European Association for the Study of Diabetes.
13 Jun 2017 Results presented at the 77th Annual Scientific Sessions of the American Diabetes Association.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com